HC Wainwright Reaffirms Buy Rating for Aquestive Therapeutics (NASDAQ:AQST)

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 96.85% from the company’s current price.

AQST has been the subject of several other research reports. Leerink Partners increased their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Aquestive Therapeutics has a consensus rating of “Buy” and a consensus target price of $8.83.

Aquestive Therapeutics Trading Up 0.2 %

NASDAQ AQST opened at $5.08 on Wednesday. Aquestive Therapeutics has a fifty-two week low of $1.55 and a fifty-two week high of $6.23. The stock has a 50 day simple moving average of $4.92 and a two-hundred day simple moving average of $3.84.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same period in the prior year, the business posted ($0.03) EPS. On average, sell-side analysts expect that Aquestive Therapeutics will post -0.48 earnings per share for the current year.

Hedge Funds Weigh In On Aquestive Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. nVerses Capital LLC purchased a new position in Aquestive Therapeutics during the third quarter valued at $28,000. Victory Capital Management Inc. purchased a new position in Aquestive Therapeutics during the second quarter valued at $27,000. SG Americas Securities LLC purchased a new position in Aquestive Therapeutics during the first quarter valued at $54,000. Harvey Capital Management Inc. purchased a new position in Aquestive Therapeutics during the third quarter valued at $88,000. Finally, International Assets Investment Management LLC purchased a new position in Aquestive Therapeutics during the third quarter valued at $990,000. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.